The company said the probe was specifically related to Cardizem's clinical experience program, which saw Biovail introducing the drug to patients through ...
Drug maker Akorn Inc. was granted approval last year from the Food and Drug Administration to market a generic version of Cardizem. ...
The investigation focuses on the Cardizem LA (diltiazem HCl) clinical program, Proving LA through Clinical Experience (PLACE). ...
Biovail receives letter related to 2003 Cardizem LA launch acitivites from US Attorney's Office The co announces that it has been notified by the United ...
Biovail Corp. says it's the target of a US federal grand jury investigation into activities surrounding the 2003 commercial launch of its Cardizem heart ...
In particular, the investigation relates to the Cardizem® LA clinical experience program, titled PLACE (Proving LA through Clinical Experience). ...
In particular, the investigation relates to the Cardizem LA clinical experience program, titled Proving LA through Clinical Experience. ...
Toronto, ON - Biovail, the Canadian manufacturer of a long-acting calcium-channel blocker product, Cardizem LA (diltiazem), has announced that it is being ...
The company, Canada's biggest publicly traded drugmaker, said in a release that it has been asked to provide evidence on the Cardizem LA launch and "intends ...
Biovail receives letter related to 2003 Cardizem LA launch acitivites from US Attorney's Office The co announces that it has been notified by the United ...